All positive (IHC 3+) and doubtful (IHC 2+) cases were screened by fl uorescence in situ hybridization (FISH). Patients with HER2 gene amplification, normal left ventricular ejection fraction ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

A new therapy was effective against ER-positive, HER2-negative breast cancers, the most common subtype. “These results will change how many breast cancers are treated,” says medical oncologist Dr.

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.